Sort
64,565 grants matching “drug discovery”
Cancer Center Support (CORE) Grant
$1,000,006Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P30 · FY2016 · CA
Therapeutic D-peptide Inhibitor of HIV Entry
$1,000,000Alan L Mueller · Navigen, Inc. · SB1 · FY2018 · AI
NQVL:QSTD:Pilot: Distributed-Entanglement Quantum Sensing of Chemical Properties (DQS-CP)
$1,000,000Ezekiel Johnston-Halperin · Ohio State University, The · · FY2024 · MPS
Collaborative Research: EPiQC: Enabling Practical-Scale Quantum Computation
$1,000,000Andrew A Houck · Princeton University · · FY2018 · CSE
Random Shear Shuttle BAC Libraries for Antimicrobial Discovery from Soil Metageno
$1,000,000Chengcang Charles Wu · Lucigen Corporation · R44 · FY2012 · AI
The Southwest National Primate Research Center
$1,000,000Kenneth Parkhurst Trevett · Texas Biomedical Research Institute · P51 · FY2010 · RR
Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.
$1,000,000Brent Keith Blackburn · Amygdala Neurosciences, Inc. · U43 · FY2023 · AA
MIN-REACH Research Evaluation and Commercialization Hub
$1,000,000Charles Craig Muscoplat · University Of Minnesota · U01 · FY2015 · HL
Botanical Dietary Supplements for Women's Health
$1,000,000University Of Illinois At Chicago · P50 · FY2005 · AT
A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids
$1,000,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2025 · CA
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2024 · AI
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci
$1,000,000Terry Roemer · Prokaryotics, Inc. · R44 · FY2019 · AI
Seriodiagnostic arrays for biodefense and emerging infectious diseases
$1,000,000David Huw Davies · Immport Therapeutics, Inc. · R44 · FY2008 · AI
Enabling Toxoplasma gondii Kinome Directed Drug Discovery
$1,000,000Reena Zutshi · Luceome Biotechnologies, Llc · R44 · FY2024 · AI
Antibiotics for Recalcitrant Infection
$1,000,000Kenneth Coleman · Arietis · R44 · FY2015 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$1,000,000Paul Sebahar · Curza Inc · R44 · FY2023 · AI
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease
$1,000,000James Lee · Id4pharma, Llc · R44 · FY2018 · CA
Therapeutic D-peptide Inhibitor of HIV Entry
$1,000,000Alan L Mueller · Navigen, Inc. · SB1 · FY2019 · AI
Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool
$1,000,000Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2022 · AI
Antibiotics for Recalcitrant Infection
$1,000,000Kenneth Coleman · Arietis · R44 · FY2016 · AI
SBIR Phase II: Proteome Epitope Tags-Based Antibody Arrays for High-Throughput, Proteome-Wide Kinase Pathway Profiling
$1,000,000Neal F Gordon · Epitome Biosystems, Inc. · · FY2005 · TIP
3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology
$1,000,000Jay Wyatt Warrick · Salus Discovery, Llc · R44 · FY2025 · AI
Assigning mode of action to phenotypically discovered anticancer leads.
$1,000,000Sergei S Makarov · Attagene, Inc. · R44 · FY2023 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA